Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
ID: 356531Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356531

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-051.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) aimed at advancing small molecule drug discovery and development for disorders of the nervous system. This cooperative agreement invites applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, allowing them to retain intellectual property rights while collaborating with NIH consultants and contract research organizations. The program is designed to facilitate the optimization and testing of drug candidates, adhering to regulatory standards and promoting diversity in research teams, ultimately seeking innovative therapeutic solutions for conditions aligned with NIH institutes such as NINDS, NIA, and NIMH. Interested applicants should prepare comprehensive applications, with key deadlines including a close date of August 18, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-051.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Blueprint Neurotherapeutics Network (BPN) funding opportunity aimed at advancing small molecule drug discovery and development for nervous system disorders. This program encourages applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, retaining intellectual property rights while collaborating with NIH consultants and contract organizations. The opportunity focuses on optimizing and testing compounds through rigorous study milestones and phases, specifically targeting conditions aligned with participating NIH institutes such as NINDS, NIA, and NIMH. Key dates encompass application openings in December 2024, with specific submission requirements and project duration not exceeding five years. The program emphasizes adherence to regulatory standards, diversity in research teams, and obtaining prior approval for clinical trials, ultimately seeking to facilitate efficient pathways for novel therapeutic solutions while mitigating risks associated with drug development. Interested applicants must prepare thorough applications, demonstrating innovative approaches and clear alignment with NIH's objectives in neuroscience research.
    Similar Opportunities
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Blueprint Neurotherapeutics Network (BPN) for small molecule drug discovery and development targeting disorders of the nervous system. This initiative invites applications for cooperative agreements (UG3/UH3) from neuroscience investigators to advance their projects through various stages of drug development, including Discovery and Development phases, while collaborating with NIH-funded consultants and specialized contract research organizations (CROs). The program emphasizes the importance of innovative approaches to treating complex neurological conditions and requires adherence to Good Laboratory Practices (GLP) and Good Manufacturing Practices (GMP). Interested applicants can find more information and submit inquiries via the NIH Grants Information email at grantsinfo@nih.gov, with applications due by August 18, 2026.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System," aimed at supporting the development of biologic therapies for nervous and neuromuscular disorders. This initiative is structured as a cooperative agreement, divided into two phases: UG3 for lead optimization and UH3 for IND-enabling activities, with a focus on specific treatment applications for these disorders. The program encourages collaboration with NIH resources, including access to contract research organizations and experienced consultants, to facilitate the development of innovative therapies. Interested applicants, including higher education institutions and nonprofits, are encouraged to apply by August 18, 2027, and can find more information at the provided NIH grants link or contact NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) invites applications for the Blueprint Neurotherapeutics Network (BPN), aimed at supporting small businesses in advancing small molecule drug discovery and development for disorders of the nervous system. This funding opportunity, categorized as a Cooperative Agreement under the U44 Small Business Innovation Research (SBIR) program, encourages applicants to conduct disease-specific assays and collaborate with NIH-funded consultants and contract research organizations to facilitate the transition of promising drug candidates from discovery to clinical testing. The program emphasizes compliance with Good Laboratory and Clinical Practices, rigorous study designs, and diversity in research teams, making it a vital resource for small businesses lacking the necessary infrastructure for clinical development. Applications will be accepted starting January 9, 2024, with a closing date of August 19, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Blueprint Neurotherapeutics Network (BPN) for Biologics, aimed at supporting biologic-based drug discovery and development for disorders of the nervous system. This initiative invites applications from U.S.-based small businesses to develop diverse therapeutic modalities, including antibodies and gene therapies, with a focus on specific nervous system disorders and a requirement for preliminary data demonstrating efficacy. The program emphasizes a phased, milestone-driven cooperative agreement, facilitating the transition of promising biotherapeutics from lead optimization to first-in-human trials while ensuring regulatory compliance and effective intellectual property management. Applications are due by January 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-24-294.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), focusing on biologic-based drug discovery and development for disorders of the nervous system. This initiative aims to solicit applications from researchers working on diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, to address various nervous system disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the U44 activity code. Interested applicants should prepare for collaboration and project development, as the estimated award date is set for December 1, 2025. For further details, potential applicants can refer to the NIH website or contact the agency directly.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), aimed at advancing biologic-based drug discovery and development for disorders of the nervous system. This initiative seeks applications from researchers focused on developing a variety of biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, specifically targeting nervous system and neuromuscular disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the UG3/UH3 activity code. Interested applicants should prepare for collaboration opportunities, as the estimated award date is set for December 1, 2025.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)" aimed at supporting research into novel small molecules that can modulate biological targets relevant to mental health, aging, drug abuse, and eye diseases. The initiative seeks to stimulate the discovery and development of in vivo chemical probes, requiring applicants to have validated starting compounds for optimization and bioassays to test new analogs. This funding is crucial for advancing the understanding of brain disease mechanisms and emphasizes projects that provide insights into significant biological processes. Interested applicants can submit proposals until January 7, 2027, with no budget limit specified, although actual needs must be indicated. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at NIH Grants.